86 related articles for article (PubMed ID: 6474521)
1. Radiation treatment planning for the localized prostatic carcinoma: methods and rationale.
Dewit L; van der Schueren E
Strahlentherapie; 1984 Aug; 160(8):474-84. PubMed ID: 6474521
[TBL] [Abstract][Full Text] [Related]
2. When should the seminal vesicles be included in the target volume in prostate radiotherapy?
Bayman NA; Wylie JP
Clin Oncol (R Coll Radiol); 2007 Jun; 19(5):302-7. PubMed ID: 17448647
[TBL] [Abstract][Full Text] [Related]
3. p53 immunohistochemical and genetic alterations are associated at high incidence with post-irradiated locally persistent prostate carcinoma.
Prendergast NJ; Atkins MR; Schatte EC; Paulson DF; Walther PJ
J Urol; 1996 May; 155(5):1685-92. PubMed ID: 8627854
[TBL] [Abstract][Full Text] [Related]
4. Feasibility of IMRT to cover pelvic nodes while escalating the dose to the prostate gland: dosimetric data on 35 consecutive patients.
Bayouth JE; Pena J; Culp L; Brack C; Sanguineti G
Med Dosim; 2008; 33(3):180-90. PubMed ID: 18674682
[TBL] [Abstract][Full Text] [Related]
5. Quality assurance of the 22961 EORTC trial. A phase III study of the optimal combination of hormonal adjuvant treatment by LHRH analogue and radiation therapy for the management of locally advanced prostate cancer: the dummy run.
Kouloulias VE; Giraud JY; Davis BJ; Dusserre A; Zurlo A; Bolla M
Radiother Oncol; 2004 Oct; 73(1):11-20. PubMed ID: 15465141
[TBL] [Abstract][Full Text] [Related]
6. The feasibility of dose escalation with three-dimensional conformal radiotherapy in patients with prostatic carcinoma.
Zelefsky MJ; Leibel SA; Kutcher GJ; Kelson S; Ling CC; Fuks Z
Cancer J Sci Am; 1995; 1(2):142-50. PubMed ID: 9166467
[TBL] [Abstract][Full Text] [Related]
7. Does intensity modulated radiation therapy (IMRT) prevent additional toxicity of treating the pelvic lymph nodes compared to treatment of the prostate only?
Guckenberger M; Baier K; Richter A; Vordermark D; Flentje M
Radiat Oncol; 2008 Jan; 3():3. PubMed ID: 18190681
[TBL] [Abstract][Full Text] [Related]
8. [Radiotherapy of localized prostatic carcinoma].
Gez E; Netzer-Horowitz Y; Waiman E; Rubinov R; Cohen Y; Kuten A
Harefuah; 1997 Dec; 133(12):593-6, 664. PubMed ID: 9451865
[TBL] [Abstract][Full Text] [Related]
9. Late urinary morbidity with high dose prostate brachytherapy as a boost to conventional external beam radiation therapy for local and locally advanced prostate cancer.
Pellizzon AC; Salvajoli JV; Maia MA; Ferrigno R; Novaes PE; Fogarolli RC; Pellizzon RJ
J Urol; 2004 Mar; 171(3):1105-8. PubMed ID: 14767280
[TBL] [Abstract][Full Text] [Related]
10. Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy.
Zelefsky MJ; Nedelka MA; Arican ZL; Yamada Y; Cohen GN; Shippy AM; Park JJ; Zaider M
Brachytherapy; 2008; 7(1):1-6. PubMed ID: 18299108
[TBL] [Abstract][Full Text] [Related]
11. Improved quality of life following radical radiation therapy for early stage carcinoma of the prostate.
Leibel SA; Pino y Torres JL; Order SE
Urol Clin North Am; 1980 Oct; 7(3):593-604. PubMed ID: 7456172
[No Abstract] [Full Text] [Related]
12. Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area.
Arcangeli S; Saracino B; Petrongari MG; Gomellini S; Marzi S; Landoni V; Gallucci M; Sperduti I; Arcangeli G
Radiother Oncol; 2007 Aug; 84(2):148-55. PubMed ID: 17692416
[TBL] [Abstract][Full Text] [Related]
13. Radiation therapy of localized prostate cancer.
Landmann C
Ann Urol (Paris); 1994; 28(4):207-20. PubMed ID: 7979211
[TBL] [Abstract][Full Text] [Related]
14. External beam radiotherapy and hyperthermia in the treatment of patients with locally advanced prostate carcinoma.
Algan O; Fosmire H; Hynynen K; Dalkin B; Cui H; Drach G; Stea B; Cassady JR
Cancer; 2000 Jul; 89(2):399-403. PubMed ID: 10918172
[TBL] [Abstract][Full Text] [Related]
15. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.
Michalski JM; Winter K; Purdy JA; Parliament M; Wong H; Perez CA; Roach M; Bosch W; Cox JD
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):706-13. PubMed ID: 15936549
[TBL] [Abstract][Full Text] [Related]
16. Australia-wide comparison of intensity modulated radiation therapy prostate plans.
Skala M; Holloway L; Bailey M; Kneebone A
Australas Radiol; 2005 Jun; 49(3):222-9. PubMed ID: 15932465
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial for the optimisation of treatment position in the radiation therapy of prostate cancer.
O'Neill L; Armstrong J; Buckney S; Assiri M; Cannon M; Holmberg O
Radiother Oncol; 2008 Jul; 88(1):61-6. PubMed ID: 18453021
[TBL] [Abstract][Full Text] [Related]
18. A prospective three-dimensional analysis about the impact of differences in the clinical target volume in prostate cancer irradiation on normal-tissue exposure. A potential for increasing the benefit/risk ratio.
Hille A; Töws N; Schmidberger H; Hess CF
Strahlenther Onkol; 2005 Dec; 181(12):789-95. PubMed ID: 16362789
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months.
Akakura K; Suzuki H; Ichikawa T; Fujimoto H; Maeda O; Usami M; Hirano D; Takimoto Y; Kamoto T; Ogawa O; Sumiyoshi Y; Shimazaki J; Kakizoe T;
Jpn J Clin Oncol; 2006 Dec; 36(12):789-93. PubMed ID: 17082219
[TBL] [Abstract][Full Text] [Related]
20. [Conformal radiation therapy with or without intensity modulation in the treatment of localized prostate cancer].
Maingon P; Bolla M; Truc G; Bosset M; Peignaux K; Ammor A
Cancer Radiother; 2005 Nov; 9(6-7):382-7. PubMed ID: 16095944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
